According to the market assessment report titled ‘Asia Pacific Regenerative Medicine Market Forecast 2027 By Application, By Type, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, Asia Pacific regenerative medicine market is slated to amass a valuation of over USD 22 billion by 2027.
 

Rising penetration of stem cell technology, and growing prevalence of chronic diseases such as Parkinson’s, arthritis, spinal cord injury among others are the major factors fueling the growth of Asia Pacific regenerative market. Further, increasing emphasis on research and innovation for novel therapies are adding considerable traction to the industry development.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4384862/

Despite the positive outlook, high costs associated with regenerative medicine therapies and a stringent regulatory landscape may inhibit market growth over the forecast period.

Considering the type of therapy, the cell therapy segment accounted for more than 50% of the total market share in 2020 and will continue to witness an upward trend in its growth rate as it is the most preferred method for restoring lost tissue function, thereby removing the need for a new organ.

Speaking of the application spectrum, the wound healing segment is expected to grow at a robust rate of 20.1% during the analysis timeline owing to high success rate of regenerative medicine in treating injured cells and tissues. Besides, rise in road accidents, sports injuries, along with improving quality of life, and increasing emphasis effective healing solutions for diabetic or venous wounds and pressure ulcers are enhancing the remuneration scope of this segment.

Meanwhile, the musculoskeletal segment is expected to reach a valuation of nearly USD 6.5 billion owing to increasing incidences of musculoskeletal conditions like rheumatoid arthritis across the region.

Geographically, the industry India looks promising in terms of growth rate due to funding from domestic and international organizations.  Moreover, high prevalence of diseases such as cancer, diabetes, eye disorders and bone and cartilage issues in the country has been favorable for the market growth.

On the other hand, increasing medical research on stem cell therapy for traumatic brain injury is significantly contributing to the industry growth in Japan.

Elaborating on the competitive landscape, major players influencing Asia Pacific regenerative medicine market trends are Orthocell Limited, Terumo BCT, Allergan Inc., and Japan Tissue Engineering Co. Ltd.